drugset / Trial / NCT01339156

Study of P3914 to Evaluate the Safety, Tolerability, Food Effect & Pharmacokinetics in Healthy Male Subjects and Efficacy & Safety of P3914 in Patients With Acute Dental Pain

NCT01339156 ↗

Phase 1 Terminated 46 enrolled Piramal Enterprises Limited
RandomizedParallel-groupQuadruple-blindTreatment

Summary

P3914 a pro-drug of Naproxen, characterized by naproxen (COX inhibiting moiety) linked to a NO moiety is intended for the treatment of pain and inflammation. The rationale behind development of P3914 is to maintain the analgesic, antipyretic and anti-inflammatory activity of naproxen and enhance GI safety by virtue of release of NO besides with no major effect on blood pressure on long-term administration.

Timeline

Start
2011-06
Primary completion
2011-11
Completion
2012-06

Drugs

EvaluationDrugModalityDoseRoute
Subject P3914 Unknown — Oral

Indications

No indication recorded.